论文部分内容阅读
目的探讨紫衫类药物用于老年乳腺癌患者新辅助化疗的疗效及不良反应。方法 70例老年乳腺癌患者随机分为观察组35例和对照组35例,其中观察组使用多西紫杉醇脂质体新辅助化疗法进行治疗,对照组使用普通紫杉醇单药化疗法进行治疗,统计比较两组患者的治疗疗效和不良反应。结果观察组化疗后的有效率是84.3%,完全缓解率是13.0%;对照组化疗后的有效率是81.5%,完全缓解率是12.2%。两组比较差异无统计学意义(P>0.05)。两组患者的不良反应发生率的比较,差异具有统计学的意义(P<0.05)。结论多西紫衫类药物对于治疗老年乳腺癌患者新辅助化疗的疗效较好,患者的不良反应较低,患者的耐受性良好,值得临床推广。
Objective To investigate the efficacy and adverse reactions of the drugs of neoadjuvant chemotherapy for elderly patients with breast cancer. Methods Seventy elderly patients with breast cancer were randomly divided into observation group (n = 35) and control group (n = 35). The observation group was treated with docetaxel liposome neoadjuvant chemotherapy. The control group was treated with paclitaxel monotherapy. Statistics The curative effect and adverse reaction of two groups were compared. Results The effective rate of the observation group after chemotherapy was 84.3% and the complete remission rate was 13.0%. The effective rate of the control group after chemotherapy was 81.5% and the complete remission rate was 12.2%. There was no significant difference between the two groups (P> 0.05). The incidence of adverse reactions between the two groups, the difference was statistically significant (P <0.05). Conclusion Docetaxel is effective in treating neoadjuvant chemotherapy in elderly patients with breast cancer. The adverse reactions of the drug are relatively low and the patients are well tolerated. It is worthy of clinical promotion.